

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
08 May 2025 (08.05.2025)



(10) International Publication Number  
**WO 2025/096954 A1**

(51) International Patent Classification:

*A61K 48/00* (2006.01) *C12N 15/86* (2006.01)  
*A61K 31/00* (2006.01) *A61K 38/28* (2006.01)  
*A61K 39/00* (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:

PCT/US2024/054131

(22) International Filing Date:

01 November 2024 (01.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/595,296 01 November 2023 (01.11.2023) US  
63/615,452 28 December 2023 (28.12.2023) US

(71) Applicant: **KRIYA THERAPEUTICS, INC.** [US/US];  
4105 Hopson Road, Morrisville, North Carolina 27560  
(US).

(72) Inventors: **STONE, Michele**; c/o Kriya Therapeutics, Inc.,  
4105 Hopson Road, Morrisville, North Carolina 27560  
(US). **SMITH, Chari**; c/o Kriya Therapeutics, Inc., 4105  
Hopson Road, Morrisville, North Carolina 27560 (US).  
**HARRINGTON, William Wallace**; c/o Kriya Therapeu-  
tics, Inc., 4105 Hopson Road, Morrisville, North Caroli-  
na 27560 (US). **QUINN, William**; c/o Kriya therapeu-  
tics, Inc., 4105 Hopson Road, Morrisville, North Carolina  
27560 (US). **FURMANSKI, Brian**; c/o Kriya Therapeu-  
tics, Inc., 4105 Hopson Road, Morrisville, North Carolina  
27560 (US). **RAMASWAMY, Shankar**; c/o Kriya Ther-  
apeutics, Inc., 4105 Hopson Road, Morrisville, North Car-  
olina 27560 (US).

(74) Agent: **NANNENGA-COMBS, Bonnie W.** et al.;  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1101  
K Street N.W., 10th Floor, Washington, District of Colum-  
bia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: AAV MEDIATED INSULIN AND GLUCOKINASE GENE THERAPY FOR TREATING DIABETES

(57) Abstract: The present disclosure relates to a combination therapy comprising a first AAV vector genome comprising an insulin expression cassette and a second AAV vector genome comprising a glucokinase expression cassette which are administered intramuscularly (e.g., to at least two skeletal muscle groups) and optionally, wherein the combination therapy is accompanied by an immuno-suppressive regimen, and methods for using the same for treating diabetes.

WO 2025/096954 A1